about
Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSafety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years OldImmunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older personsImmunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adultsNeisseria meningitidis: biology, microbiology, and epidemiology.Evaluation of serum bactericidal antibody assays for Haemophilus influenzae serotype a.Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV.First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Vaccination strategies to prevent tuberculosis in the new millennium: from BCG to new vaccine candidates.Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.Cardiac manifestations of parasitic infections part 1: overview and immunopathogenesis.Cardiac manifestations of parasitic infections. Part 2: Parasitic myocardial disease.Cardiac manifestations of parasitic infections part 3: pericardial and miscellaneous cardiopulmonary manifestations.Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular SignaturesInfections associated with haemophagocytic syndrome.Spectrum of CNS disease caused by rapidly growing mycobacteria.Molecular signatures of antibody responses derived from a systems biology study of five human vaccinesAspergillus endocarditis: a review of the literature.Systems biology of vaccination in the elderly.Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.Metabolic Phenotypes of Response to Vaccination in Humans.Case report: atypical Lemierre's disease secondary to Porphyromonas asaccharolytica.Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects."Bazex syndromes": dissimilar entities named after the same father![Hirsutism]Evolution.Pleural effusion in a patient with AIDS.A real-time polymerase chain reaction for the detection of Streptococcus pneumoniae in blood using a mouse model: a potential new "gold standard".Use of 2 pneumococcal common protein real-time polymerase chain reaction assays in healthy children colonized with Streptococcus pneumoniae.Skin Ulcers Misdiagnosed as Pyoderma GangrenosumCytomegalovirus Prostatitis in a Heart Transplant RecipientA Painful Thorn in the Foot: A Case of EumycetomaCharacterization of flares in patients with systemic lupus erythematosus: Comment on the article by Ho et alRapid generation of neutralizing antibody responses in COVID-19 patients
P50
Q30204573-A7DB4698-523A-4917-9F10-6F1C0600EF38Q30369098-9E124D25-08D3-4230-A29B-50763F293D15Q30371419-D13A67E3-36A0-48D9-B529-5DA8EFDC251DQ30419062-698FEA18-FFB5-484E-B157-F71D10F37E7EQ34602462-E3CC8E94-53CF-4A44-8827-2202DADF7CE3Q34632986-7CDF03F8-6D0F-43FD-BD61-F097439468C6Q34738896-28E48B36-40BD-4E14-805C-048C8DF5904CQ35133349-F51B62B1-CBFD-4882-A92B-4259CDAF296DQ35858437-9838133C-6528-4660-85CA-502C1AA08130Q36353206-603EF3D2-CEA3-4AFC-A8C5-8969C7E3F5C1Q36612595-9655BFC7-3046-4321-BEDD-DD390095C16AQ36795395-26545EC5-1A40-413A-A158-3B5B0216B978Q36816968-3A0B5738-45F2-40E5-B26D-C2BE5992F748Q36841694-AA3196F4-19AE-4B2F-B53A-A6F99E0D450FQ36879291-507380A7-C787-49B0-B8E1-3D3B2CD3159EQ37018227-FE5FF86E-B2CF-4CC5-96C1-D538E4C5AA88Q37172588-D32DED79-E66F-4B14-8D17-38E48E39A85AQ37625332-30134D7B-A1F4-4822-9140-C476B7363535Q37805166-D60D27A1-D3FE-467E-BC63-6EA5C99E26AAQ38035764-DCF06CF4-7B03-42E4-95CA-4287BFFF525AQ38380006-CEDF0F1C-6AAC-4825-BB01-40DD296BEC9DQ38422597-62C18784-C7F9-4E5C-BABF-BABF0D688914Q38422603-7F2C1E4F-1D20-4D45-809E-038695B41C95Q40162587-3AD7122A-DEB8-4D5B-A046-1C9A17823A57Q40202000-76A79CC7-BDB5-47A5-B461-07FB8297B5B9Q40391588-662C6431-4B50-4813-9FA6-540AC66CF3FCQ41122192-5C116D96-873E-4661-9CB8-8C924E384611Q42518238-92942A9F-3877-4720-BBDB-CBCC919F3DD4Q44222937-D1D7D7B2-1C4F-4D3D-8EEE-80AA5FD6A11FQ46511604-19372FFA-E7C9-4CB3-A002-836541C7A497Q46550286-80852914-C371-49D5-B7DC-CA54C7DD0ED4Q47579345-275B4CD5-0C21-4EAF-8855-6ED81F5E46D0Q54383461-AC48F194-D2A5-4D95-80EB-728267EDC6A7Q58880010-1B30D844-62DA-4ADA-9D17-2AECF70087DFQ61714807-E766C699-ACA3-45A7-8EC8-44701353CA92Q61714812-4672F891-FDAB-4AC9-B404-342CCD56C10DQ61714814-0A777CCB-EC7C-474B-A3B3-138A92FA3D24Q95602889-9748C7A2-9133-4A4B-B2AF-11DB314E8A7B
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nadine Rouphael
@ast
Nadine Rouphael
@en
Nadine Rouphael
@es
Nadine Rouphael
@nl
Nadine Rouphael
@sl
type
label
Nadine Rouphael
@ast
Nadine Rouphael
@en
Nadine Rouphael
@es
Nadine Rouphael
@nl
Nadine Rouphael
@sl
prefLabel
Nadine Rouphael
@ast
Nadine Rouphael
@en
Nadine Rouphael
@es
Nadine Rouphael
@nl
Nadine Rouphael
@sl
P106
P1153
23052616600
P21
P31
P496
0000-0002-2512-7919